Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Development candidates in pipeline (candidates): 26.00 candidates in Q2 2026, down 13.3% from a year earlier.
Latest, Q2 2026
26.00
Period ended Jun 30, 2026
Change on a year earlier
-13.3%
30.00 in Q2 2025
History
30 quarters
Since Q4 2018
Sources
28
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 1 & MD&A Overview.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development candidates in pipeline (candidates) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 26.00 | -13.3% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 25.00 | -19.4% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 25.00 | -26.5% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 30.00 | -16.7% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 30.00 | -25.0% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 31.00 | -22.5% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 34.00 | -19.0% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2024 | Sep 30, 2024 | 36.00 | -12.2% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 40.00 | -11.1% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 40.00 | -11.1% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 42.00 | -6.7% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 41.00 | -6.8% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 45.00 | +4.7% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 45.00 | +4.7% | Q1 2023 10-Q ↗ |
| Q4 2022 | Dec 31, 2022 | 45.00 | +21.6% | FY2024 10-K ↗ |
| Q3 2022 | Sep 30, 2022 | 44.00 | +29.4% | Q3 2022 10-Q ↗ |
| Q2 2022 | Jun 30, 2022 | 43.00 | – | Q2 2022 Earnings Release (8-K) ↗ |
| Q1 2022 | Mar 31, 2022 | 43.00 | +43.3% | Q1 2022 10-Q ↗ |
| Q4 2021 | Dec 31, 2021 | 37.00 | +76.2% | FY2021 10-K ↗ |
| Q3 2021 | Sep 30, 2021 | 34.00 | +47.8% | Q3 2021 10-Q ↗ |
| Q1 2021 | Mar 31, 2021 | 30.00 | +25.0% | Q1 2021 10-Q ↗ |
| Q4 2020 | Dec 31, 2020 | 21.00 | -12.5% | FY2021 10-K ↗ |
| Q3 2020 | Sep 30, 2020 | 23.00 | +9.5% | Q3 2021 10-Q ↗ |
| Q2 2020 | Jun 30, 2020 | 23.00 | +9.5% | Q2 2020 10-Q ↗ |
| Q1 2020 | Mar 31, 2020 | 24.00 | +14.3% | Q1 2020 10-Q ↗ |
| Q4 2019 | Dec 31, 2019 | 24.00 | +14.3% | FY2019 10-K ↗ |
| Q3 2019 | Sep 30, 2019 | 21.00 | – | Q3 2019 10-Q ↗ |
| Q2 2019 | Jun 30, 2019 | 21.00 | – | Q2 2019 10-Q ↗ |
| Q1 2019 | Mar 31, 2019 | 21.00 | – | Q1 2019 10-Q ↗ |
| Q4 2018 | Dec 31, 2018 | 21.00 | – | FY2018 10-K ↗ |
Cite this data
StockData. (2026). Moderna Development candidates in pipeline (candidates), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/pipeline-candidates
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.